ReviewTissue barriers2018
Pathophysiology of IBD associated diarrhea.
Review in Tissue barriers, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
92 citing papers in PubMed, 2 syntheses or guidelines pooled it, 188 citations in OpenAlex.
- Pooled it
- Potassium channels in intestinal epithelial cells and their pharmacological modulation: a systematic review.American journal of physiology. Cell physiology · 2021Pooled it
- A Novel Epigenetic Mechanism of Intestinal NHE3 Gene Regulation by Histone Acetylation.International journal of molecular sciences · 2026Article
- Article
- Association Between Chronic Diarrhea and Relative Fat Mass: A Cross-Sectional Study Based on NHANES.Digestive diseases and sciences · 2026Article
- Berberine in Inflammatory Bowel Disease: Integrative Regulation of the Microbiota-Immune-Barrier Axis.International journal of molecular sciences · 2026Review
- Antidiarrheal activity of the 80% methanol extract and solvent fractions of the leaves of Thymus schimperi (Lamiaceae) in mice.Scientific reports · 2026Article
- Targeting the Cyclic GMP-AMP Synthase-Stimulator of Interferon Genes Pathway: An Emerging Therapeutic Strategy for Digestive Diseases.Clinical and translational gastroenterology · 2026Review
- Isoliquiritigenin alleviates ulcerative colitis by enhancing the intestinal barrier and improving intestinal microbiota via inhibiting the TLR4/MyD88/NF-κB pathway.Scientific reports · 2026Article
- Natural triterpenoid Ardisiacrispin B attenuates colitis-associated cancer via JAK2/STAT3 pathway and gut microbiota modulation.Natural products and bioprospecting · 2026Article
- Revolutionizing Crohn's disease detection: integrating AI with intestinal ultrasound for superior diagnosis.Therapeutic advances in gastroenterology · 2026Article
- Modeling Gut Barrier Dysfunction and Subsequent Opportunistic Infection by Candida albicans During Chemotherapy-Induced Intestinal Mucositis in Mice.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Vitamin D3 mediates amelioration of ulcerative colitis via the TRPV1-MAPK signaling pathway.Frontiers in immunology · 2026Article
- Wuji Wan ameliorates ulcerative colitis by restoring impaired membrane transport.Frontiers in pharmacology · 2026Article
- Investigations of the voltage-gated CaFrontiers in pharmacology · 2026Article
- Selective Nanoparticulate Systems for Drug Delivery in Inflammatory Bowel Disease.Pharmaceutics · 2025Review
- Development and validation of a novel patient-reported outcome for microscopic colitis-Microscopic Colitis Score (MCS).Journal of Crohn's & colitis · 2025Article
- Mechanism of Regulation of NaCl Homeostasis in the Distal Colon During Obesity.International journal of molecular sciences · 2025Article
- Metagenomic estimation of absolute bacterial biomass in the mammalian gut through host-derived read normalization.mSystems · 2025Article
- Chloride channels and mast cell function: pioneering new frontiers in IBD therapy.Molecular and cellular biochemistry · 2025Review
32 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Inflammatory bowel diseases broadly categorized into Crohn's disease (CD) and ulcerative colitis (UC), are chronic inflammatory disorders of the gastrointestinal tract with increasing prevalence worldwide. The etiology of the disease is complex and involves a combination of genetic, environmental, immunological and gut microbial factors. Recurring and bloody diarrhea is the most prevalent and debilitating symptom in IBD. The pathogenesis of IBD-associated diarrhea is multifactorial and is essentially an outcome of mucosal damage caused by persistent inflammation resulting in dysregulated intestinal ion transport, impaired epithelial barrier function and increased accessibility of the pathogens to the intestinal mucosa. Altered expression and/or function of epithelial ion transporters and channels is the principle cause of electrolyte retention and water accumulation in the intestinal lumen leading to diarrhea in IBD. Aberrant barrier function further contributes to diarrhea via leak-flux mechanism. Mucosal penetration of enteric pathogens promotes dysbiosis and exacerbates the underlying immune system further perpetuating IBD associated-tissue damage and diarrhea. Here, we review the mechanisms of impaired ion transport and loss of epithelial barrier function contributing to diarrhea associated with IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.